DDW Editor Reece Armstrong offers three key takeaways from Optimum’s Annual Healthcare Investor Conference. 

AI is still dominating the conversation

AI was an obvious talking point throughout the conference, with its application in both investing and in drug discovery and development being major points of discussion. As someone who regularly reports on the technology’s use in drug discovery, it was interesting to hear about how investors are utilising AI to identify what they called ‘rising stars’ in the biotech sector. In the panel session, “AI’s role in shaping biotech investment narratives,” it was made clear that AI was helping investment companies speed up company analysis. However, whilst efficiency was the major driver of AI’s usage, some panellists were worried about how it can remove the nuance required by investors when it comes to choosing which biotechs to pursue. What became clear is that a human element is still key in this sector and that investors need to do their due diligence and understand just exactly why a biotech might be a strong contender for funding and not simply rely on an algorithm to point them towards companies.

The EU faces challenges 

In an afternoon session focused on Europe, it was made clear that the EU is no longer the centre for innovation. Challenges such as navigating the regulatory environments and a lack of venture capital for larger funding rounds were noted as being significant hurdles. And despite the EU market being large, the fact that insurers and governments often won’t pay for innovative therapies means that developers are looking towards other markets such as the US where they can be reimbursed. A later session was more positive about EU funding in smaller rounds, but agreed with the lack of large-scale funding impacting the market.

2026 a strong year overall

Despite global turmoil, 2026 has been a strong year for biotech. This year has seen 26 IPOs and pre-IPOs have almost hit 2001. The conference noted that China has been the biggest success story in recent times. One panel noted how that 46% of all new clinical trials were launched in China this year, showcasing the effort the country has gone to in order to make it a biotech hub for research. Another success story noted during the conference was the number of new drug approvals made by the FDA this year, despite the organisation suffering from a lot of staff turnover in recent years under the Trump administration.  With 46 new drug approvals this year already, the administration has already surpassed last year’s figure, showcasing that the US market has managed to survive its turbulent politics and support one of its strongest sectors.

References

1: https://www.biobucks.co/biotech-vc-funding-tracker-2026